Efepoetin alfa

DB19197InvestigationalProtein Based Therapies

Efepoetin alfa is under investigation in clinical trial NCT04155125 (A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient).

Mechanism: Pharmacologically active on Erythropoietin receptor
Curator reviewed
Also known as: Erythropoietin (human) fusion protein with immunoglobulin (synthetic hybrid fc fragment hyfc) · Human erythropoietin (epoetin alfa) fused to a hybrid human immunoglobulin (ig), consisting of the fc fragment of the igg4 fused to the hinge and amino-terminus of the igd heavy chain isotype 2, produced in chinese hamster ovary (cho) cells, glycoform al

Resolves to

Compound

UNIIR6OS9S8VQ7CAS1905452-78-9

Clinical / RWD

ATCB03XA10

Targets

P19235EPOR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 2 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Efepoetin alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account